Selected article for: "patient group and randomized study"

Author: Dabbous, Hany M.; Abd-Elsalam, Sherief; El-Sayed, Manal H.; Sherief, Ahmed F.; Ebeid, Fatma F. S.; El Ghafar, Mohamed Samir Abd; Soliman, Shaimaa; Elbahnasawy, Mohamed; Badawi, Rehab; Tageldin, Mohamed Awad
Title: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
  • Cord-id: 5rm5g9e2
  • Document date: 2021_1_25
  • ID: 5rm5g9e2
    Snippet: No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ gr
    Document: No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation. ClinicalTrials.gov Identifier NCT04351295.

    Search related documents:
    Co phrase search for related documents